Allogene Therapeutics, Inc.: financial statements

ALLONASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.63

November 20, 2026Market cap $217M

What Ploutos Investor adds for Allogene Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 42% since Nov 5, 2026, when the 10-Q these figures come from was filed ($1.09 then, $0.63 on Nov 20, 2026). The figures date from before that move.10-Q
  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

Line202320242025Average a year
Revenue $95.0K$22.0K$0
Operating income -$328M-$273M-$209M
Net income -$327M-$258M-$191M
Earnings per share -$2.09-$1.32-$0.87
Earnings per share, basic -$2.09-$1.32-$0.87
Margins
Operating margin -344,986.3%-1,241,813.6%–
Net margin -344,489.5%-1,170,863.6%–

Financial statements

ALLO's revenue, profits and cash flows from 2019 to 2022, 4 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$83M Leases0.0% Effective tax rate

The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Leases

Dec 31, 2025

Operating leases

$83M

Finance leases

–

Average discount rate
6.5%
Lease cost for the year
$9.8M

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

Operating lease payments by year

Lease liability by year

Leases

ALLO's leases from 2019 to 2022, 4 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

0.0%

-21.0 pts

The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Tax credits

+0.9 pts

Change in valuation allowance

-18.6 pts

Share-based compensation

-3.3 pts

Non-deductible expenses

-0.1 pts

Effective rate

0.0%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Effective tax rate by year

In a year of a loss or of very small profits the rate comes out negative or very large and says little. Those years are in grey.

Effective tax rate by year

The tax rate ALLO paid on its profit, from 2018 to 2022, 5 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Claims ahead of shareholders

What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.

$96M securities and stakes

Other than debt, no claim large enough to list ranks ahead of the shares.

On the other side, it holds $96M of long-term securities and stakes in other companies, at the value in its accounts, about 44% of the market value.

On the other side

at Sep 30, 2026
$96M

From the balance sheet of September 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 20, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.

The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.

The full analysis

What do Allogene Therapeutics's filings show?

These are Allogene Therapeutics's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ALLO's financials

Didn't find what you were looking for?

Ask us
How much revenue did ALLO have in 2025?

Allogene Therapeutics had revenue of $0 and net income of -$191M in fiscal 2025, a net margin of .

How much debt does ALLO have?

On December 31, 2025 Allogene Therapeutics had total assets of $416M, debt of – and shareholders' equity of $293M.

How much free cash flow does ALLO have?

In fiscal 2025 Allogene Therapeutics had cash from operations of -$149M and spent $386.0K on capital expenditure, leaving -$150M of free cash flow.

Where are the figures from?

From Allogene Therapeutics, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.